Protagonist raises $40m to test oral peptides in IBD
This article was originally published in Scrip
Executive Summary
Protagonist Therapeutics raised $40m in Series C venture capital to take its first oral peptide drug candidate PTG-100 into clinical trials for the treatment of inflammatory bowel diseases (IBD).
You may also be interested in...
Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor
J&J's Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL-23 inhibitor for Crohn's disease, which hits a similar target as two key assets in J&J's immunology portfolio: Stelara and the Phase III biologic guselkumab.
Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
The number of US biopharma IPOs during the first 11 months of 2016 – 29 companies went public – is less than half of the 2015 total of 62, but stock performance has improved as investors focus on quality.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.